BMRN: Chief Accounting Officer resignation; interim coverage by CFO

Rhea-AI Filing Summary

BioMarin Pharmaceutical Inc. announced that Erin Burkhart, Group Vice President and Chief Accounting Officer, notified the company of her voluntary resignation effective September 2, 2025. The company will search for a successor and, if none is appointed by the effective date, Brian Mueller, Executive Vice President and Chief Financial Officer, will serve as principal accounting officer in addition to his CFO duties. The filing states Ms. Burkhart's departure is not due to any disagreement with the company. Mr. Mueller will not receive additional compensation for performing the accounting officer role and has no reportable related-party transactions.

Positive

• Planned transition with interim coverage by the CFO maintains continuity in accounting leadership
• Resignation described as voluntary and not due to disagreement, reducing immediate governance concern
• No additional compensation for the CFO while performing interim principal accounting officer duties

Negative

• Key accounting vacancy that could strain resources if a successor is not appointed promptly
• Concentration of roles in the CFO increases reliance on a single executive for finance and accounting oversight

Insights

Corporate Accounting Officer

Temporary coverage by the CFO limits near-term operational disruption.

The resignation of the chief accounting officer creates a key leadership vacancy in the accounting function. Appointing the CFO as interim principal accounting officer preserves continuity in financial oversight and external reporting responsibilities through the transition.

This arrangement concentrates responsibilities in one executive, which increases dependency on the CFO's bandwidth and could affect internal control oversight if prolonged. Expect the company to complete an external or internal search within a typical hiring window of several weeks to a few months.

Investor Relations Advisor

Disclosure is neutral and follows reporting norms for officer departures.

The company explicitly states the resignation is voluntary and not due to disagreement, which reduces immediate governance concern. The filing also confirms no compensation change for the interim role and no related-party transactions for the interim appointee.

Investors may monitor the appointment timing and the background of any successor for accounting expertise; any prolonged vacancy or appointment of a less-experienced successor could be material to perceptions of financial control quality over the next quarter.

0001048477false00010484772025-08-052025-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-26727

68-0397820

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

770 Lindaro Street

San Rafael

California

94901

(Address of Principal Executive Offices)

(Zip Code)

(415) 506-6700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001

BMRN

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 5, 2025, Erin Burkhart, the Group Vice President, Chief Accounting Officer and principal accounting officer of BioMarin Pharmaceutical Inc. (the Company) notified the Company of her decision to resign, effective as of September 2, 2025 (the Effective Date). Ms. Burkhart’s departure is voluntary and is not related to any disagreement between Ms. Burkhart and the Company.

The Company will initiate a search for Ms. Burkhart’s successor. In the event that the Company has not appointed a successor on or prior to the Effective Date, Brian Mueller, the Company’s Executive Vice President and Chief Financial Officer, will serve as the Company’s principal accounting officer from the Effective Date until Ms. Burkhart’s successor is appointed. Mr. Mueller will continue to serve as the Executive Vice President and Chief Financial Officer of the Company. Mr. Mueller’s biographical information is disclosed in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2025. Mr. Mueller has not engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation S-K. Mr. Mueller will not receive any adjustment to his compensation or any additional compensation in connection with performing the functions of the principal accounting officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						BioMarin Pharmaceutical Inc., a Delaware corporation
Date: August 11, 2025			By:			/s/ G. Eric Davis
						G. Eric Davis
						Executive Vice President, Chief Legal Officer

FAQ

What did BioMarin (BMRN) disclose about its chief accounting officer?

Erin Burkhart notified the company of her voluntary resignation effective September 2, 2025 and her departure is not due to any disagreement with the company.

Who will serve as BioMarin's principal accounting officer after the resignation?

Brian Mueller, the company's Executive Vice President and Chief Financial Officer, will serve as principal accounting officer if a successor is not appointed by September 2, 2025.

Will the interim principal accounting officer receive extra pay?

No; the filing states Mr. Mueller will not receive any adjustment or additional compensation for performing the functions of principal accounting officer.

Does the filing report any related-party transactions involving the interim appointee?

No; the filing states Mr. Mueller has not engaged in any transaction that would be reportable as a related-party transaction under Item 404(a) of Regulation S-K.

Will BioMarin search for a successor to the chief accounting officer?

Yes; the company will initiate a search for a successor and will appoint one when the search concludes.